Please login in order to access this content. Click "Continue" to proceed or "Return" to return to LillyMedical.com.
You are now leaving the LillyMedical.com Web site
Please select the therapeutic area you would like to see more about.
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
HUMULIN® R U-500 (insulin human injection): Pharmacokinetics and Pharmacodynamics Clinical Experience
The time action characteristics reflect both prandial and basal activity attributed to the high concentration of Humulin R U-500.
published references below are available by contacting 1-800-LillyRx
de la Peña A, Riddle M, Marrow LA, et al. Pharmacokinetics and
pharmacodynamics of high-dose human regular U-500 insulin versus
human regular U-100 insulin in healthy obese subjects. Diabetes
Care. 2011;34(12):2496-2501. http://dx.doi.org/10.2337/dc11-0721
de la Peña A, Ma X, Reddy S, et al. Application of PK/PD
modeling and simulation to dosing regimen optimization of high-dose
human regular U-500 insulin. J Diabetes Sci Technol.
Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for
human regular U-500 insulin in patients with type 2 diabetes not
achieving adequate glycemic control on high-dose U-100 insulin
therapy with or without oral agents: a randomized,
titration-to-target clinical trial. Endocr Pract.
= Humulin® R U-500 (insulin human injection) 500 units/mL
Date of Last Review:April 16, 2018
Are you satisfied with this content?
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.